Blurred hospital corridor with healthcare staff and patient care rooms
Blurred hospital corridor with healthcare staff and patient care rooms
Logo

Clinical manufacturing solutions for research in cell and gene therapies

Cell and gene therapy, where and when it matters most

Patients in clinical studies rely on you at a time when they are most vulnerable. That is when our decades of unwavering commitment to advancing the life sciences and cell therapy means the most.

Miltenyi Biotec has been driving progress in cell and gene therapy (CGT) for over 25 years. Helping advance therapies to clinical settings, our expertise in instruments, reagents, and services facilitates fast and standardized point-of-care manufacturing of autologous and allogeneic therapies. We also recognize the dynamic nature of medicine and the importance of staying ahead. Thus, our core competence in innovation focuses on empowering flexible, complete workflows that meet the evolving needs of clinicians.

Whether for immuno-oncology, graft engineering, autoimmune disease, or regenerative medicine, our product portfolio covers workflow steps from cell separation to in-process and quality control, ensuring precise and efficient outcomes. You define what is possible. We help you make it a reality.

View cell and gene therapy solutions by indication

Illustration showing lymphoma

Lymphoma

CGT advances to improve outcomes in treating lymphoid cell malignanciesSee more
Illustration showing lymphoma

Lymphoma

CGT advances to improve outcomes in treating lymphoid cell malignanciesSee more
Illustration showing blood vessels

Leukemia

Promising CGT options for cancers of blood cells in early stages of differentiationSee more
Illustration showing blood vessels

Leukemia

Promising CGT options for cancers of blood cells in early stages of differentiationSee more
Illustration showing a tumor

Solid cancers

Cell therapies at the turning point of successfully treating solid tumorsSee more
Illustration showing a tumor

Solid cancers

Cell therapies at the turning point of successfully treating solid tumorsSee more
Illustration showing two antibody symbols

Autoimmune diseases

A new frontier of CGT tackles imbalances of immunity and toleranceSee more
Illustration showing two antibody symbols

Autoimmune diseases

A new frontier of CGT tackles imbalances of immunity and toleranceSee more

Myeloma

CGT aims for long-term remission in cancers of plasma cellsSee more

Myeloma

CGT aims for long-term remission in cancers of plasma cellsSee more

Monogenic diseases of the blood

Engineered CGT and grafts to safely treat inborn errors of bloodSee more

Monogenic diseases of the blood

Engineered CGT and grafts to safely treat inborn errors of bloodSee more

Post-transplant complications

Progress in fine-tuning transplants to tip the balance towards toleranceSee more

Post-transplant complications

Progress in fine-tuning transplants to tip the balance towards toleranceSee more
Illustration showing two kidneys

Solid organ transplantation

Supporting immune modulation in transplant settings with cell therapy and apheresisSee more
Illustration showing two kidneys

Solid organ transplantation

Supporting immune modulation in transplant settings with cell therapy and apheresisSee more
Decorative image showing a patient and indications
Illustration showing lymphoma

Lymphoma

CGT advances to improve outcomes in treating lymphoid cell malignanciesSee more
Illustration showing lymphoma

Lymphoma

CGT advances to improve outcomes in treating lymphoid cell malignanciesSee more
Illustration showing blood vessels

Leukemia

Promising CGT options for cancers of blood cells in early stages of differentiationSee more
Illustration showing blood vessels

Leukemia

Promising CGT options for cancers of blood cells in early stages of differentiationSee more
Illustration showing a tumor

Solid cancers

Cell therapies at the turning point of successfully treating solid tumorsSee more
Illustration showing a tumor

Solid cancers

Cell therapies at the turning point of successfully treating solid tumorsSee more
Illustration showing two antibody symbols

Autoimmune diseases

A new frontier of CGT tackles imbalances of immunity and toleranceSee more
Illustration showing two antibody symbols

Autoimmune diseases

A new frontier of CGT tackles imbalances of immunity and toleranceSee more

Myeloma

CGT aims for long-term remission in cancers of plasma cellsSee more

Myeloma

CGT aims for long-term remission in cancers of plasma cellsSee more

Monogenic diseases of the blood

Engineered CGT and grafts to safely treat inborn errors of bloodSee more

Monogenic diseases of the blood

Engineered CGT and grafts to safely treat inborn errors of bloodSee more

Post-transplant complications

Progress in fine-tuning transplants to tip the balance towards toleranceSee more

Post-transplant complications

Progress in fine-tuning transplants to tip the balance towards toleranceSee more
Illustration showing two kidneys

Solid organ transplantation

Supporting immune modulation in transplant settings with cell therapy and apheresisSee more
Illustration showing two kidneys

Solid organ transplantation

Supporting immune modulation in transplant settings with cell therapy and apheresisSee more
Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain
Prof. Carlos Fernández de Larrea, Hospital Clinic Barcelona, Spain

Discover how leading cell therapy centers are implementing point-of-care manufacturing approaches to expand patient access and accelerate innovation

Setting the benchmark in cell and gene therapy solutions

Icon showing a healthcare professional and a stethoscope with a number counting to 150+ below, representing the number of clinical trials

Pioneering more than 200 cell therapy trials with PoC manufacturing and analytics*

Infusion bag icon stating 7/8 below

Approved engineered T cell therapies are manufactured using Miltenyi Biotec's solutions**

Icon showing a lightbulb with a gear inside and a number counting to 25+ below, representing innovation

Over 25 years of CGT expertise and relentlessly pushing boundaries

*Active cell therapy trials and hospital treatments using CliniMACS® Instruments for manufacturing and/or analytics of cell products
** Approved cell therapies and gene-modified cell therapies in Europe and USA, excluding minimally manipulated cell therapies, cord blood products, and tissue-engineered therapies

Patients in clinical studies trust you. We have your back.

We prioritize efficacy and safety within the context of real-world, clinical-scale manufacturing settings. That promise goes beyond an instrument purchase. With world-class service and technical support, we understand your unique requirements and help build the infrastructure to meet your intended use and throughput.

The evidence is clear. Our technologies help realize more than 100,000 cell therapy workflows, clinical trials, and treatments for over 6,000 patients annually. Have a look at our reference lists detailing our involvement.

Cell and gene therapy technologies that transform care

Increased accessibility

Imagine a world where life-saving interventions are not always bound by traditional supply chains. Envision care where critical medical cases without access to commercial therapy are prioritized through efficient and accessible Point-of-Care (PoC) manufacturing.

Designed for automated and scalable GMP-compliant cell manufacturing, the CliniMACS Prodigy® Platform helps you and your team make a profound impact on delivering cell and gene therapies. Increase patient access to treatment by reducing vein-to-vein time and eliminating the carbon footprint and expense of off-site logistics through decentralized manufacturing.

Define the next decade of therapy.

Explore the CliniMACS Prodigy
Clinical employee in clean room attire setting up a cell manufacturing process on the CliniMACS Prodigy

Tailored workflows

Realize your PoC manufacturing through our Cell Manufacturing Enabling Package (CMEP), a modular training and support program. Whether you are just starting out or scaling up, move from project launch to full clinical CAR T cell manufacturing in as little as 12 months. Built on more than 25 years of experience in cell and gene therapy, it gives you standardized protocols, adaptable documentation templates, regulatory guidance, and hands-on training. The complete package ensures you can start with confidence and keep moving forward.

When you need a workflow tailored to your specific process requirements, our Customized Application Services team works with you to achieve it. We translate manual protocols into integrated, GMP-compliant processes on the CliniMACS Prodigy. Each project includes workflow design, control documentation, and training to ensure precision at every step.

Clinical employees in clean room attire setting up a cell manufacturing process on the CliniMACS Prodigy

Reliable analytics

Picture clinical decisions supported by quick and dependable data at the point of care. Achieve consistent in-process control and release testing with analytical solutions designed for decentralized CGT manufacturing.

Our standardized flow cytometry workflows help reduce variability, support regulatory readiness, and generate comparable results across sites, so you can advance therapies with confidence.

Browse PoC analytics solutions
Scientist looking at a sample, standing in front of a flow cytometer, performing cell and gene therapy analytics on the MACSQuant Analyzer 16 flow cytomer, CliniMACS Prodigy in a clean room in the background

Knowledge and experience in cell and gene therapy

Transformation builds on the know-how of a community. Tap into a wealth of experience and insights from within Miltenyi Biotec and from the global CGT community. Partake in training courses and engage with your network of CGT experts to advance your work.

Stay ahead in your field

Sign up for our newsletter to keep up to date with latest field developments, case studies, and networking events.

Do you need expert advice? Connect with us today.

You have previously chosen International as your location.
What do you want to do?